Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer's Future in China Looks Healthy
- ChinaBio Today submits: Pfizer (NYSE: PFE) announced two new collaborations with China academic institutions last week. Neither one was targeted at developing a specific drug candidate. Instead, their goal appeared to be building long-term relationships with academic leaders in China’s scientific community. Even though it has built a large,...
- External links 2009-08-02
- Sinovac Testing Swine Flu Vaccine
- ChinaBio Today submits: Six weeks after receiving their first samples of the A/H1N1 swine flu virus, two China biotechs have begun clinical trials of vaccines for the potentially fatal version of flu. Sinovac Biotech Ltd. SVA and Hualan Biological Engineering will each test their vaccines in about 2,000 volunteers,...
- External links 2009-07-23
- Luminex Opens Shanghai Center to Meet China Demands for Lab Equipment
- ChinaBio Today submits: Luminex Corporation (NSDQ: LMNX), a Texas-based maker of multiplexed research tools, has opened a Shanghai office that will serve as the company’s operations center for the Asia Pacific region. The company said demand in China for its products was both strong and growing. The new facility...
- External links 2009-06-03
- Pfizer: Looking to Do Deals in Emerging Markets
- ChinaBio Today submits: Pfizer Inc (NYSE: PFE) will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China. Currently, Pfizer occupies the number three position. The emerging markets sector is worth $80 billion currently, and is expected to grow...
- External links 2009-06-21
- GSK Seeks to Increase Emerging Markets Presence with New Vaccine JV
- ChinaBio Today submits: GlaxoSmithKline (NYSE: GSK) has formed a vaccine JV with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established China vaccine company. The JV will produce flu vaccines for the China market. It will seek to increase GSK’s presence in emerging markets, which is one of the...
- External links 2009-06-10
- AstraZeneca's Latest Cost-Cutting Move: Offshore Production
- ChinaBio Today submits: In a continuing attempt to cut costs, the Anglo-Swedish big pharma AstraZeneca (NYSE: AZN) said it would move all of its API production offshore, with most of it going to China. The company will close a plant in the UK that manufactures APIs for cholesterol and...
- External links 2009-12-01
- Pfizer's Cutbacks Reflect Difficulties Facing Big Pharma
- ChinaBio Today submits: Pfizer (NYSE: PFE) announced it would close six out of its 20 R&D facilities around the globe as part of its post-Wyeth-acquisition consolidation. Some employees will be transferred to other facilities, while others will be let go. Pfizer did not disclose how many of its R&D...
- External links 2009-11-10
- NeoStem Closes China Biopharma Acquisition to Boost Revenues
- ChinaBio Today submits: NeoStem, Inc. NBS announced it has closed its acquisition of China Biopharmaceuticals Holdings, Inc. (CHBP.OB). China Biopharma’s sole asset is a 51% stake in Suzhou Erye Pharmaceutical Co., a 50-year old pharmaceutical company that expects to generate $60 million in revenue and net income of $12...
- External links 2009-11-03
- Merck Serono to Spend $225 Million on New Beijing R&D Center
- ChinaBio Today submits: Merck Serono, a division of Germany’s Merck KGaA MRK, will build a global R&D center in Beijing, China, spending $225 million over the next four years. The center, which will eventually house 200 employees, will be the fourth major R&D center for the company. The Beijing...
- External links 2009-11-25
- GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B
- ChinaBio Today submits: GlaxoSmithKline GSK and Gilead Sciences GILD agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® tenofovir disoproxil fumarate. GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore,...
- External links 2009-11-25
- Pfizer Is Best Positioned Big Pharma in China - Goldman
- ChinaBio Today submits: In an investment review of Pfizer (NYSE: PFE), Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer. Goldman expects...
- External links 2009-11-20
- Advanced BioMedical Finds Partner for New Use of Medical Device
- ChinaBio Today submits: Advanced BioMedical Technologies (ABMT.OB) said its operating subsidiary, Shenzhen Changhua Biomedical Engineering Co. (ABT-Changhua), has signed a cooperative agreement to develop its Polyamide (PA) bio-absorbable material in new applications. Together with the First Affiliated Hospital of Guangdong Pharmaceutical University in Guangzhou, the company will conduct research...
- External links 2009-11-18
- Abbott Labs Wins Approval for Drug Eluting Stent
- ChinaBio Today submits: Abbott Labs (NYSE: ABT) was given SFDA approval for its Xience V drug eluting stent system as a treatment for coronary artery disease (CAD), the leading cause of death in China. The approval was based on two worldwide clinical trials that enrolled 1302 patients, including 60...
- External links 2009-09-15
- Sinovac Listed in Deloitte Technology Fast 50 China 2008
- ChinaBio Today submits: Sinovac Biotech Ltd. SVA said its main operating entity, Sinovac Beijing, was named to the Deloitte Technology Fast 50 China 2008. A vaccine maker, Sinovac’s revenues derive mainly from its hepatitis A vaccine, Healive. The company also makes a combination hepatitis A & B vaccine, a flu...
- External links 2008-11-04
- American Oriental Announces Two Acquisitions
- ChinaBio Today submits: American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...
- External links 2008-10-23
- Charles River and Shanghai BioExplorer Open CRO Facility
- ChinaBio Today submits: Charles River Laboratories International, Inc. CRL formally opened its 60,000 square foot preclinical facility in Shanghai. The international CRO and Shanghai BioExplorer formed a JV called Charles River Preclinical Services Greater China, which owns and runs the facility, with Charles River being the majority partner. Charles...
- External links 2008-10-16
- Mindray's Q3 Leaves Investors Less Than Pleased
- ChinaBio Today submits: On the face of it, the Q3 financial report issued by Mindray Medical International MR was very positive. Revenues were up 94% at $146.5 million and non-GAAP net income climbed a smaller but still respectable 48% to $33.7 million. Nevertheless, Mindray’s stock price suffered in the...
- External links 2008-11-11
- Novo Nordisk Expands R&D Presence in China with New Manufacturing Plant
- ChinaBio Today submits: Novo Nordisk NVO will invest almost $400 million to build a very large insulin manufacturing facility in Tianjin. The new facility will function as the company’s primary production site in China and serve the entire Asia Pacific region. The new 22,500 sq. meter plant, which will...
- External links 2008-11-11
- TomoTherapy Reduces Dependency on Single Linear Accelerator Manufacturer
- ChinaBio Today submits: TomoTherapy TOMO of Madison, Wisconsin, which makes the Hi•Art treatment system for advanced radiation therapy, will buy privately held Chengdu Twin Peak Accelerator Technology Inc., located in the provincial capital of Sichuan, China. Twin Peak produces linear accelerators, which are used in radiation therapy systems to...
- External links 2008-11-07
Additional Resources
- China Biotech in Review: Deals and Healthcare Stimulus
- ChinaBio Today submits: In a quiet week that was constrained by the Thanksgiving Day holiday in the U.S., news flow from China biopharma slowed, but refused to disappear entirely. Last week’s articles show that, despite a worldwide economic crisis, deals continue to be done in the China biopharma sector....
- External links 2008-11-30
- << Previous
- page 1 of 1
- Next >>
